Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis

Arthritis Care and Research

Volumn 65, Issue 11, 2013, Pages 1828-1834

  Wang, Chen ^a   Gou, Shen Ju ^a   Chang, Dong Yuan ^a   Yu, Feng ^a   Zhao, Ming Hui ^a   Chen, Min ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; HIGH MOBILITY GROUP B1 PROTEIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; BLOOD LEVEL; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; REMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HMGB1 PROTEIN; HUMANS; KIDNEY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84887085811     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22187     Document Type: Article

References (33)

1. Segelmark M, Wieslander J,. IgG subclasses of antineutrophil cytoplasm autoantibodies (ANCA). Nephrol Dial Transplant 1993; 8: 696-702.
2. Falk RJ, Jennette JC,. ANCA small-vessel vasculitis. J Am Soc Nephrol 1997; 8: 314-22.
3. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, et al. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 2001; 20: 4337-40.
4. Seong SY, Matzinger P,. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004; 4: 469-78.
5. Urbonaviciute V, Voll RE,. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med 2011; 270: 309-18.
6. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003; 48: 971-81.
7. Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, et al. High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 2011; 17: 29-35.
8. Wibisono D, Csernok E, Lamprecht P, Holle JU, Gross WL, Moosig F,. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis [letter]. Ann Rheum Dis 2010; 69: 1888-9.
9. Henes FO, Chen Y, Bley TA, Fabel M, Both M, Herrmann K, et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 2011; 70: 1926-9.
10. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
11. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007; 66: 605-17.
12. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-8.
13. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, for the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
15. Zhao MH, Lockwood CM,. A comprehensive method to purify three major ANCA antigens: proteinase 3, myeloperoxidase and bactericidal/permeability-increasing protein from human neutrophil granule acid extract. J Immunol Methods 1996; 197: 121-30.
16. Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, et al. High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 2008; 14: 109-15.
17. Bajema IM, Hagen EC, Hansen BE, Hermans J, Noel LH, Waldherr R, et al. The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. Nephrol Dial Transplant 1996; 11: 1989-95.
18. Bajema IM, Hagen EC, Hermans J, Noel LH, Waldherr R, Ferrario F, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 1999; 56: 1751-8.
19. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002; 61: 80-9.
20. Kokkola R, Andersson A, Mullins G, Kaya Z, Muller OJ, Pleger ST, et al. RAGE is the major receptor for the pro-inflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61: 1-9.
21. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in the cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7.
22. Bianchi ME,. HMGB1 loves company. J Leukoc Biol 2009; 86: 573-6.
23. Wang H, Yang H, Tracey KJ,. Extracellular role of HMGB1 in inflammation and sepsis. J Int Medicine 2004; 255: 320-31.
24. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007; 13: 2836-48.
25. Sobajima J, Ozaki S, Uesugi H, Osakada F, Shirakawa H, Yoshida M, et al. Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC). Clin Exp Immunol 1998; 111: 402-7.
26. Jiang W, Pisetsky DS,. Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus [letter]. Ann Rheum Dis 2008; 67: 727-8.
27. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, de Marchis F, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205: 3007-18.
28. Abdulahad DA, Westra J, Bijzet J, Dolff S, van Dijk MC, Limburg PC, et al. Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthritis Res Ther 2012; 14: R184.
29. Scaffidi P, Misteli T, Bianchi ME,. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
30. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565-70.
31. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001; 152: 1197-206.
32. Kallenberg CG,. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis 2011; 70: i59-63.
33. Shi Y, Sandoghchian Shotorbani S, Su Z, Liu Y, Tong J, Zheng D, et al. Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis [abstract]. Clin Dev Immunol 2012; 2012: 295081.